Home » Orthovita Receives Clearance for Vitoss Bone Graft Substitute
Orthovita Receives Clearance for Vitoss Bone Graft Substitute
Orthovita, Inc. … announced Tuesday that it received 510(k) clearance from the U.S. Food and Drug Administration to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities.
TradingMarkets
TradingMarkets
Upcoming Events
-
07May
-
14May
-
30May